Oral Vancomycin as an Adjuvant Treatment in IBD

Ayers, Travis D; Leonard-Puppa, Elaine; Kader, Howard A.; Waddell, Jaylyn; Watkins, Runa; Blanchard, Samra; Safta, Anca; Rawal, Nidhi

doi:10.1093/crocol/otz015

Cited by 3 publications

(1 citation statement)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Oral vancomycin has been considered an effective medication for IBD treatment [ 10 , 11 ], compared to traditional antibiotics, vancomycin has a better side effect profile without increasing the risk for vancomycin-resistant enterococcus [ 12 , 13 ]. However, Ayers and his colleagues indicated that oral vancomycin treatment might be an effective treatment option for IBD in the short and long term [ 14 ]. In addition, Tannock et al reported that oral vancomycin treatment is effective in patients with colitis and suggested a possible relationship between its ability to treat UC and its effect on the vancomycin-sensitive bacteria in the gut microbiota [ 15 ], which affect the severity of colitis by attracting neutrophils into damaged colon tissue, thereby to increased colon inflammation [ 16 ].…”

Section: Introductionmentioning

confidence: 99%

Evaluation of microbial and vancomycin treatments in ulcerative colitis in murine models

Hasan

Yang

2023

PLoS ONE

View full text Add to dashboard Cite

Background Despite the number of available therapies for ulcerative colitis (UC), severe side effects and high cost has limited their clinical application. Thus, finding new alternative strategies with minimal side effects is inevitable. Therefore, this study aimed to compare the effectiveness of different therapeutic approaches in DSS-induced colitis. Methods Firstly, we designed oral bio-therapeutic products, Live Bacterial Products (LBP), which include a mixture of fecal bacteria strains isolated from healthy mice and prepared by microencapsulation and freeze-dried techniques. Then we investigated the efficiency of 7 days of freeze-dried FMT, LBP, and vancomycin treatments in DSS-induced colitis. Secondly, we compared the effect of 15 days of microbial therapies (freeze-dried powder of FMT and LBP microcapsules) and seven days of oral vancomycin on the severity of colitis in mice. Furthermore, the levels of IL-1β and TNF-α were measured in serum by ELISA, and the fecal microbiota diversity was analyzed by high-throughput sequencing for all mice groups. Results After seven days of treatments, our results indicated that oral vancomycin reduced the severity of DSS-induced colitis in mice, where weight gain and a decrease in IL-1 β and TNF-α levels were observed in the vancomycin group compared with other treatment groups. While after two weeks of treatment, the LBP microcapsules were able to reduce the severity of colitis. And at the end of the treatment period, weight gain and a decrease in the DAI scores and the levels of IL-1β and TNF-α were noted in the LBP treatment group compared to other treatment groups. By high-throughput sequencing of the 16S rRNA gene, our results showed that while the microcapsules LBP treatment increased the fecal microbial diversity, after vancomycin therapy, most of the fecal microbiota genera and operational taxonomic units (OTUs) were depleted. Conclusion Our results concluded that treatment duration and preparation methods affect the microbial therapies’ efficiency in UC. Furthermore, this study highlighted the negative consequences of oral vancomycin administration on gut health that should be known before using this medication.

show abstract